Indivior (INDV) Receives “Outperform” Rating from Royal Bank Of Canada
Royal Bank Of Canada restated their outperform rating on shares of Indivior (LON:INDV) in a research note published on Friday morning, MarketBeat reports. The brokerage currently has a GBX 500 ($6.73) price objective on the specialty pharmaceutical company’s stock.
Other research analysts have also recently issued reports about the company. Stifel Nicolaus reaffirmed a buy rating and set a GBX 400 ($5.38) price objective on shares of Indivior in a research report on Friday, September 15th. Numis Securities reaffirmed a buy rating and set a GBX 470 ($6.33) price objective on shares of Indivior in a research report on Friday, September 15th. Morgan Stanley reissued an equal weight rating and issued a GBX 410 ($5.52) target price on shares of Indivior in a research report on Friday. Jefferies Group upped their target price on Indivior from GBX 358 ($4.82) to GBX 472 ($6.35) and gave the company a buy rating in a research report on Thursday, November 9th. Finally, Citigroup reissued a neutral rating and issued a GBX 280 ($3.77) target price on shares of Indivior in a research report on Thursday, October 26th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of GBX 472.43 ($6.36).
Indivior (LON INDV) opened at GBX 369.70 ($4.98) on Friday. Indivior has a 1 year low of GBX 246.50 ($3.32) and a 1 year high of GBX 421.50 ($5.67).
Indivior Company Profile
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.
Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.